Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory of Molecular Genetics |
RCV001375003 | SCV001572291 | likely pathogenic | Neurodevelopmental disorder | 2020-12-10 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002322362 | SCV002626268 | uncertain significance | Inborn genetic diseases | 2025-01-31 | criteria provided, single submitter | clinical testing | The c.1159G>A (p.E387K) alteration is located in exon 9 (coding exon 9) of the CTSF gene. This alteration results from a G to A substitution at nucleotide position 1159, causing the glutamic acid (E) at amino acid position 387 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |